PRTA Jan 2025 22.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:29PM EDT. Market open.
Loading interactive chart…
- Zacks
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
- Business Wire
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
DUBLIN, May 28, 2024--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
- Simply Wall St.
News Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation plc (NASDAQ:PRTA) Forecasts
Celebrations may be in order for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, with the analysts delivering a...
© 2024 Yahoo. All rights reserved.